Pancreatic Islet Transplantation Into the Gastric Submucosa

Type 1 Diabetes Clinical Trial

Official title:

Treatment of Type I Diabetes by Pancreatic Islet Transplantation Into The Gastric Submucosa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01571817
• Other study ID #: Islet-Tx-Sub-DERC
• Status: Completed
• Phase: Phase 1
• Start date: April 2012
• Est. completion date: December 2014

Study information

• Verified date: August 2020
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall objective of this pilot project is to evaluate the safety and efficacy of the gastric submucosal space as a novel site for clinical islet transplantation. The site has several physiologic attributes that may improve the outcomes of islet transplantation compared with the conventional intraportal transplant site.

Description:

The overall objective of this pilot project is to evaluate the safety and efficacy of the gastric submucosal space as a novel site for clinical islet transplantation. Safety will be evaluated by the monitoring of side effects such as post procedural GI complications, frequency of hypo and hyperglycemic events, and immunosuppression side effects. Efficacy will be determined by accepted measures including insulin independence, long term glucose control, and reduction/elimination of hypoglycemic events.

The site has several physiologic attributes that may improve the outcomes of islet transplantation compared with the conventional intraportal transplant site.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Key Inclusion Criteria:

1. Primary islet allotransplant

2. Type I diabetes mellitus for a minimum of 5 years

3. One or more of the following signs or symptoms despite intensive efforts made in close cooperation with their diabetic care team:

• Metabolic lability/instability characterized by hypoglycemia or ketoacidosis (>2 hospital admissions in the previous year), erratic glucose profiles (MAGE>120 mg/dL), or disruption in lifestyle of danger to life, self or others

• Reduced awareness of hypoglycemia or >1 episode in the last 1.5 years of severe hypoglycemia

• Persistently poor glucose control (as defined by HgbA1c>10% at the end of six months of Intensive management efforts with the diabetes care team)

• Progressive secondary complications as defined by (i) a new proliferative retinopathy or clinically significant macular edema or therapy with photocoagulation during the last year; or (ii) symptomatic autonomic neuropathy (as defined by postural hypotension or neuropathic bladder)

4. Age 18 and older

5. Patients who have a renal transplant must have received their transplant at least 3 months previously and must have stable renal function (see exclusion criteria below)

6. Must be able to give written informed consent

Exclusion Criteria:

Key Exclusion Criteria:

1. Lymphopenia (<1000/µL) or leukopenia ( <3000 total leukocytes/µL)

2. Presence of panel-reactive anti-HLA antibody >20%

3. Positive lymphocytotoxic cross-match using donor lymphocytes and serum

4. Evidence of acute EBV infection (IgM>IgG) OR no serologic evidence of previous exposure to EBV (IgG>IgM)

5. Calculated or measured GFR < 50 ml/min/m2 in patients without a renal transplant.

6. Calculated or measured GFR < 40 ml/min/m2 in patients with a renal transplant.

7. Portal hypertension or history of significant liver disease

8. History of malignancy within 10 years (except for treated basal or squamous cell CA of the skin)

9. Active peptic ulcer disease or other gastric mucosal abnormalities as identified on screening endoscopy

10. Severe unremitting diarrhea or other GI disorders potentially interfering with the ability to absorb oral medications

11. Untreated proliferative retinopathy

12. Pregnancy or breastfeeding

13. Female subjects not post-menopausal or surgically sterile who are sexually active but not using an acceptable method of contraception

14. Active infections

15. Serologic evidence of infection with HIV, or HbsAg or HCV Ab positive

16. Major ongoing psychiatric illness

17. Ongoing substance abuse, drug or alcohol; or recent history of noncompliance

18. Any condition that in the opinion of the Principal Investigator does not allow safe participation in the study

-

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Biological:
• Isolated Human Pancreatic Islets

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Andrew Posselt

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Hypo- and Hyper-glycemia limits for blood glucose related risks; during procedure, abdominal pain, duodenal hemorrhage, and duodenal perforation post-procedure, fever, cytokine release syndrome (to the thymoglobulin), immunosuppression related issues	Six months